{"id":"https://openalex.org/W56850475","doi":null,"title":"Development and Characterization of Anti-CD20-NKG2D-Ligand Fusion Proteins","display_name":"Development and Characterization of Anti-CD20-NKG2D-Ligand Fusion Proteins","alternate_titles":[],"publication_year":2011,"publication_date":"2011-01-01","ids":{"openalex":"https://openalex.org/W56850475","mag":"56850475"},"language":"en","primary_location":{"id":"mag:56850475","doi":null,"is_oa":false,"landing_page_url":"https://scholarlyrepository.miami.edu/oa_theses/303/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W56850475"],"child_works_count":0,"type":"dissertation","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5024687815","display_name":"Patrice N Harris","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Patrice N Harris","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5024687815"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.8378999829292297,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11020","display_name":"Immune Cell Function and Interaction","score":0.8378999829292297,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.13899999856948853,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.006000000052154064,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cd20","display_name":"CD20","score":0.8840000033378601},{"id":"https://openalex.org/keywords/nkg2d","display_name":"NKG2D","score":0.8529999852180481},{"id":"https://openalex.org/keywords/nkg2d-ligands","display_name":"NKG2D ligands","score":0.9509999752044678},{"id":"https://openalex.org/keywords/fusion-protein","display_name":"fusion protein","score":0.7900000214576721},{"id":"https://openalex.org/keywords/rituximab-resistance","display_name":"rituximab resistance","score":0.8339999914169312},{"id":"https://openalex.org/keywords/nk-cell-activation","display_name":"NK cell activation","score":0.7260000109672546},{"id":"https://openalex.org/keywords/antibody-dependent-cellular-cytotoxicity","display_name":"antibody-dependent cellular cytotoxicity","score":0.8740000128746033},{"id":"https://openalex.org/keywords/fc-gamma-receptor","display_name":"Fc gamma receptor","score":0.8529999852180481},{"id":"https://openalex.org/keywords/b-cell-malignancies","display_name":"B-cell malignancies","score":0.8410000205039978},{"id":"https://openalex.org/keywords/non-hodgkin-lymphoma","display_name":"non-Hodgkin lymphoma","score":0.9200000166893005},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.6349999904632568}],"concepts":[{"id":"https://openalex.org/C2778867473","wikidata":"https://www.wikidata.org/wiki/Q17544382","display_name":"NKG2D","level":4,"score":0.7120992541313171},{"id":"https://openalex.org/C40677261","wikidata":"https://www.wikidata.org/wiki/Q21418091","display_name":"Antibody-dependent cell-mediated cytotoxicity","level":4,"score":0.614890456199646},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.5947544574737549},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.531940758228302},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5188797116279602},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.45049750804901123},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.4445475935935974},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.4099274277687073},{"id":"https://openalex.org/C154317977","wikidata":"https://www.wikidata.org/wiki/Q376266","display_name":"Cytotoxic T cell","level":3,"score":0.40044093132019043},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.35248470306396484},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3504331111907959},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.33820435404777527},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.32716891169548035},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.12049612402915955},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.09736025333404541}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:56850475","doi":null,"is_oa":false,"landing_page_url":"https://scholarlyrepository.miami.edu/oa_theses/303/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":24,"referenced_works":["https://openalex.org/W60759546","https://openalex.org/W1595098530","https://openalex.org/W1603913234","https://openalex.org/W1914229355","https://openalex.org/W1915689252","https://openalex.org/W1976285978","https://openalex.org/W1976835009","https://openalex.org/W2033485934","https://openalex.org/W2044360617","https://openalex.org/W2056645320","https://openalex.org/W2057796652","https://openalex.org/W2058015212","https://openalex.org/W2064920472","https://openalex.org/W2079756029","https://openalex.org/W2125770488","https://openalex.org/W2128402413","https://openalex.org/W2146102054","https://openalex.org/W2150679053","https://openalex.org/W2154643481","https://openalex.org/W2160305510","https://openalex.org/W2163790170","https://openalex.org/W2167571754","https://openalex.org/W2169578616","https://openalex.org/W2264636885"],"related_works":["https://openalex.org/W1974917518","https://openalex.org/W2980336458","https://openalex.org/W4242734012","https://openalex.org/W2560817153","https://openalex.org/W1974735199","https://openalex.org/W2578360777","https://openalex.org/W1986974587","https://openalex.org/W2172473781","https://openalex.org/W2593977422","https://openalex.org/W2309133506"],"abstract_inverted_index":{"CD20":[0,22,270,277,315],"is":[1,24,34,118,149,186,195,236],"a":[2,27,35,121,150,202,269,294],"35kDa":[3],"surface":[4],"antigen":[5,23],"expressed":[6,196],"on":[7,26,154,290],"B":[8,18,30,54],"cells":[9,249,280,292,319],"from":[10],"the":[11,16,21,50,74,85,105,136,175,178,187,206,239,255,321],"early":[12,190],"pre-B":[13],"stage":[14],"through":[15,245,320],"mature":[17],"stage.":[19],"Moreover,":[20],"found":[25],"majority":[28],"of":[29,52,76,90,107,124,140,174,241,247],"cell":[31,55,126,176],"malignancies.":[32],"Rituximab":[33,108,141],"chimeric":[36],"anti-CD20":[37,242,252],"monoclonal":[38],"antibody":[39,113,253],"which":[40,169,194],"has":[41,110,201],"been":[42],"extensively":[43],"used":[44],"alone":[45],"or":[46],"in":[47,49,73,84,137,142,171,209,324],"combination":[48],"treatment":[51,75],"CD20+":[53],"malignancies":[56],"including":[57],"acute":[58],"lymphoblastic":[59],"leukemia":[60,68],"(ALL),":[61],"non-Hodgkin\u2019s":[62],"lymphomas":[63],"(NHL)":[64],"and":[65,128,157,200,281,307,316],"chronic":[66],"lymphocytic":[67],"(CLL),":[69],"as":[70,72,120],"well":[71],"numerous":[77],"autoimmune":[78],"disorders.":[79],"Despite":[80],"its":[81,310],"emerging":[82],"use":[83],"clinic,":[86],"30%":[87],"to":[88,99,103,219,237,266,276,286,312],"50%":[89],"patients":[91],"with":[92,262],"low-grade":[93],"NHL":[94],"exhibit":[95],"no":[96],"clinical":[97],"response":[98],"Rituximab.":[100],"Previous":[101,260],"work":[102],"elucidate":[104],"mechanisms":[106],"resistance":[109],"established":[111],"that":[112,129,215,268,302],"dependent":[114,296],"cellular":[115,198],"cytotoxicity":[116],"(ADCC)":[117],"important":[119],"predominant":[122],"mechanism":[123],"lymphoma":[125],"clearance":[127],"Fc\u03b3":[130],"receptors":[131,289],"(Fc\u03b3Rs)":[132],"are":[133],"critical":[134],"for":[135,183,205,309],"vivo":[138],"actions":[139],"NHL.":[143],"Natural":[144],"killer":[145,159],"group":[146],"2D,":[147],"NKG2D":[148,185,207,221,288,322],"major":[151],"activating":[152,167],"receptor":[153,208,323],"T":[155],"lymphocytes":[156],"natural":[158],"cells.":[160],"The":[161],"NKG2D\u2013ligand":[162],"(NKG2D-L)":[163],"interaction":[164],"triggers":[165],"an":[166,216,251,283],"signal":[168,285],"results":[170,261],"cytotoxic":[172],"lysis":[173],"expressing":[177,278],"ligand.":[179,259],"One":[180],"potential":[181],"ligand":[182],"murine":[184,220],"retinoic":[188],"acid":[189],"1\u03b2":[191],"(Rae-1\u03b2)":[192],"protein":[193,273],"during":[197],"stress":[199],"high":[203],"affinity":[204],"mice.":[210],"We":[211],"have":[212],"recently":[213],"shown":[214],"anti-HER2-IgG3":[217],"fused":[218],"Ligand,":[222],"Rae1\u03b2":[223],"inhibited":[224],"HER2+":[225],"tumor":[226,279],"growth":[227],"significantly":[228],"more":[229],"than":[230],"Herceptin":[231],"alone.":[232],"Similarly,":[233],"our":[234],"objective":[235],"enhance":[238],"performance":[240],"directed":[243],"therapy":[244],"activation":[246,258,284],"NK":[248,257,318],"by":[250],"encoding":[254],"same":[256],"anti-HER2-IgG3-Rael\u03b2":[263],"led":[264],"us":[265],"hypothesize":[267],"specific":[271],"fusion":[272],"will":[274],"bind":[275,313],"deliver":[282],"local":[287],"effector":[291],"triggering":[293],"non-Fc\u03b3R":[295],"anti-tumor":[297],"response.":[298],"Here":[299],"we":[300],"show":[301],"anti-CD20-NKG2D-L":[303],"can":[304],"be":[305],"synthesized":[306],"tested":[308],"ability":[311],"human":[314],"activate":[317],"vitro.":[325]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W56850475","counts_by_year":[],"updated_date":"2026-07-14T23:32:53.992493","created_date":"2016-06-24T00:00:00"}
